OUHSC Research News – Monday, April 3, 2023
Workshops and Seminars
SPINPLUS Funding Database Webinar
Date: Tuesday, April 4, 2023 – 12:00 -1:00 pm Central Time
Location: Online
With: Bill DeCocco, InfoEd
Description: SPINPlus is a funding search database available to all faculty, staff, and students. The system provides both text and keyword search modes. Attendees of the SPINPlus session will learn how to create an account, search for funding opportunities and narrow results by setting filters. We will also explore saving searches along with activating SMARTS e-mail notifications. This webinar will cover basic login, searches, and notifications from the system.
Registration: https://ousurvey.qualtrics.com/jfe/form/SV_9RlqAQk3rdL3o5U
2023 Innovations in Aging Day
Please join the Oklahoma Dementia Care Network, the OU College of Medicine Section of Geriatrics and Palliative Medicine, and the OU Hudson College of Public Health for the 2023 Innovations in Aging Day, Tuesday April 18, 2023, 12:15pm to 4pm (virtually), held in conjunction with Careers in Aging WeekThere will be a cash prize ($250) for the 3 best abstracts, plus an invitation to present at the conference! Click the link below to enter the competition.
Registration link: https://www.ouhealth.com/events-calendar/event-details/?event=30523
Save the Date! Spring for Research Days 2023
April 4 – April 5
Save the date for OU-Tulsa’s annual Spring for Research Days (formerly Research Week), April 4 – April 5, 2023.
Save space on your calendar for these great opportunities to learn more about research conducted by OU-Tulsa students, residents, faculty, and staff.
Lightning Round Session
11am to 12pm |Schusterman Library Gallery
Research Forum
2pm to 4pm | Founder’s Hall, OU-Tulsa Learning Center
Call for Presentations - 29th Annual Zarrow Mental Health Symposium
Description: Mental Health Association Oklahoma seeks presentation proposals from presenters around the globe interested in sharing information about treatment modalities, programs, research findings, policies and practices that are informed by science and use creative and innovative approaches to mental health. Presentations utilizing technology, innovative collaborations, new treatment and program models, and emerging knowledge and methodologies are encouraged.
Application must be submitted via the online portal found at zarrowsymposium.org, no later than Friday, April 7, 2023 to be eligible for consideration.
Questions: Please contact JoBeth Hamon at 405.898.8704 or jhamon@mhaok.org.
Additional information: Please refer to the attached flyer.
OCRID 10th Annual Research Symposium
Date: Tuesday, April 11, 2023, 8:00 AM – 6:00 PM CDT
Location: McKnight Center for the Performing Arts, 705 West University Avenue Stillwater, OK 74074
Description: The Oklahoma Center for Respiratory and Infectious Diseases is a multi-institutional center with investigators coming from Oklahoma State University, University of Oklahoma, and the Oklahoma Medical Research Foundation.
The OCRID Annual Research Symposium provides an opportunity for researchers and students in the fields of respiratory and infectious diseases to gather, network, and learn together from a group of outstanding local and national leaders in their fields. Research disciplines include molecular biology, pathology, animal models, disease pathogenesis, therapeutics, molecular mechanisms, and bioengineering.
The one-day symposium features keynote speakers, showcases the progress of OCRID investigators’ projects and the update from OCRID core facilities, and hosts a poster competition with cash prizes. A catered breakfast, refreshment breaks, and lunch will be provided throughout the day.
Registration and additional information: Please refer to the attached flyers.
OUHSC Funding Opportunities
Request for applications: Genetic CRISPR Screening Pilot Award Program from the Oklahoma Nathan Shock Center on Aging and Oklahoma Center for Therapeutic Sciences
The Oklahoma Nathan Shock Center on Aging (NSC) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Pilot Awards in target and pathway discovery in cell-based models of aging and age-associated disease using high throughput screening and arrayed sgRNA CRISPR technologies. Please see the attached RFA for more details.
Office of Technology Commercialization presents the following opportunity for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).
- Ipsen, a global biopharmaceutical company, is seeking novel and innovative leads to treat rare diseases and rare neuroscience disease indications. A range of therapeutic areas, targets, and mechanisms-of-action and classes of molecules are of interest, with a specific focus on small molecule, peptide, biologics, nucleic acids, RNA therapies and antibody conjugates. Out of scope are gene therapy, cell therapy, vaccines, generics and natural products. Submission entails a 1-pg non-confidential proposal form, including workplan and budgetary requirements. (deadline 4/12).
- Astellas Pharma is seeking research related to direct reprogramming to achieve transdifferentiation of cells to another functional type in order to discover therapeutic interventions for degenerative diseases. Direct reprogramming of cells to cell types related to CNS, Lung, Heart, Kidney, Liver, Gut, Skin and Eye are of particular interest; all methods of in vivo reprogramming considered. Cell therapy, cell transplantation, biomaterial-based therapy and CRISPR/Cas systems are out of scope. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26).
- Cumulus Oncology is looking to engage with academics who have highly tumor-restricted antigens or moloclonal or multvalent antibodies that target them with potential for therapeutic activity in cancer. Embryonic cell targets are priority but others considered if sufficient tumor-specific activity to minimize off-target effects. Solid tumors are highest interest but all cancers are within scope. Out of scope: drug repurposing, small molecule, small antibodies, ADC, immunotoxins, radioimmunotherapy, gene therapy and call based therapeutics. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26).
- A global pharmaceutical company is looking to identify novel methods for discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets through passive permeation, endocytosis or via transporters. Novel in vitro assays for prediction of bioavailability/intracellular targeting with proven translation to in vivo models are also of interest. Out of scope: use of well-known cell-penetrating peptides (unless significant innovation is demonstrated) and drug delivery systems/formulation strategies. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 4/26)
NIH Notices
- Revising the NIH/AHRQ/NIOSH Post-Submission Material Policy
(NOT-OD-23-106)
- Notice of Pre-Application Webinar for RFA-AG-24-009, Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional)
(NOT-AG-23-018)
- Notice to Extend the Response Date for NOT-AI-23-017, "Request for Information (RFI): Seeking Stakeholder Input on Enhancing Diversity, Equity, Inclusion, and Accessibility Across NIAID Extramural Activities"
(NOT-AI-23-041)
- Notice of NCI Virtual Workshop to Engage Multi-Cancer Detection (MCD) Assay Developers
(NOT-CA-23-055)
- Notice of Joint NIGMS/NSF Initiative to Support A Science of Science Approach to Analyzing and Innovating the Biomedical Research Enterprise (SoS:BIO)
(NOT-GM-23-038)
- Notice of Early Expiration of NOT-HD-22-043 "Notice of Special Interest ( NOSI ): Implementation Science to Advance Maternal Health and Maternal Health Equity for the IMPROVE initiative"
(NOT-HD-23-008)
- Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in PAR-23-120, Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)
(NOT-AI-23-040)
- Notice to Extend NCCIH's PAR-20-218, PAR-20-217, PAR-20-216, PAR-20-215, and PAR-20-219
(NOT-AT-24-003)
- Notice of Correction to Application Due Dates in PAR-22-049 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)"
(NOT-CA-23-054)
- Notice of Participation of the National Institute of Nursing Research (NINR) in PAR-23-122, "Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)"
(NOT-NR-23-010)
- Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities
(NOT-OD-23-105)
- Notice of Special Interest (NOSI): Administrative Supplement for Collaborative Projects Supported by the NIAID RNCP and CCRP
(NOT-AI-23-037)
- Notice of Special Interest of NCCIH in PAR-22-097/098, "Global Brain and Nervous System Disorders Research Across the Lifespan (R01/R21 Clinical Trial Optional)
(NOT-AT-24-001)
- Notice of Special Interest (NOSI): Encouraging Womens Health Research within the NIDCD Mission Areas
(NOT-DC-23-006)
- Notice of Special Interest (NOSI): Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities
(NOT-MD-23-008)
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)
(PAR-23-132)
Application Receipt Date(s): May 07, 2026
- NIDCR Research Grants for Analyses of Existing Genomics Data (R01) (Clinical Trial Not Allowed)
(PAR-23-133)
Application Receipt Date(s): May 07, 2026
- Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
(PAR-23-148)
Application Receipt Date(s): May 07, 2026
- Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
(PAR-23-152)
Application Receipt Date(s): May 07, 2026
- Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
(PAR-23-153)
Application Receipt Date(s): May 07, 2026
- Animal Models for Hepatitis B and C (R01 Clinical Trial Not Allowed)
(RFA-AI-23-022)
Application Receipt Date(s): August 25, 2023
- Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
(RFA-CA-23-023)
Application Receipt Date(s): June 02, 2023
- Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional)
(RFA-MH-23-260)
Application Receipt Date(s): June 20, 2023
- Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional)
(RFA-NS-23-021)
Application Receipt Date(s): February 02, 2024
- Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional)
(RFA-NS-23-022)
Application Receipt Date(s): February 02, 2024
- Request for Applications (RFA): Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01, Clinical Trial Optional)
(RFA-OD-23-015)
Application Receipt Date(s): June 19, 2023
- NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional)
(RFA-RM-23-005)
Application Receipt Date(s): August 18, 2023
- NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
(RFA-RM-23-006)
Application Receipt Date(s): September 01, 2023
- NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)
(RFA-RM-23-007)
Application Receipt Date(s): September 06, 2023
Other Funding Opportunities
Cystic Fibrosis (CF) Foundation
Application Deadline: May 11, 2023
CF Foundation NIH K-Boost Award
Description: This award is designed to provide a $50,000 per year supplement to an NIH K-award that has a CF focus.
Application Deadline: Rolling applications must be submitted online at awards.cff.org.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/cf-foundation-nih-k-boost-award
CF Foundation/NIH K-Unfunded Award
Description: This award is designed to provide support for investigators with meritorious NIH K applications that were not selected for funding as they revise and resubmit.
Application Deadline: Rolling applications must be submitted online at awards.cff.org.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/cf-foundationnih-k-unfunded-award
CF Research Additional Mentoring Program (RAMP)
Description: The RAMP Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.
Application Deadline: Applications must be submitted online at awards.cff.org by May 23, 2023.
For questions, please contact Elizabeth Yu (eyu@cff.org).
Link to Full Announcement: https://www.cff.org/researchers/research-additional-mentoring-program-award
The American Heart Association Clinical Fellow Research Education Program
Description: This program will provide funding for cardiology and select neurology fellows in accredited fellowship programs to attend an AHA scientific meeting (Scientific Sessions or the International Stroke Conference, respectively) and gain other training and experience integral to development of research acumen. This includes ACGME-accredited cardiology subspecialty programs and ACGME- or UCNS-accredited vascular/neuroendovascular/geriatric neurology subspecialty programs. Institutions are strongly encouraged to use funding for fellows from racial and ethnic groups underrepresented in medicine and science. Awards will be three years in duration and will support up to five fellows annually.
Application Deadline: April 13, 2023
Link to Full Announcement: https://professional.heart.org/en/research-programs/aha-funding-opportunities/a2c-clinical-fellow-research-education-program
The Lung Cancer Research Foundation (LCRF) – Daiichi Sankyo – AstraZeneca Research Grant on Antibody Drug Conjugates
Description: LCRF is pleased to announce a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. This competitive funding mechanism will provide up to $270,000 in funding over a two-year period.
The LCRF - Daiichi Sankyo - AstraZeneca Research Grant on Antibody Drug Conjugates will develop further understanding of the mechanism of action and biomarkers for TROP2 directed ADCs in lung cancer and HER2 directed ADCs in HER2 mutant NSCLC and primary and acquired resistance to TROP2 directed and HER2 directed ADCs.
Application Deadline: May 31, 2023
Link to Full Announcement: Complete details including eligibility criteria and application instructions may be found on the LCRF website.
Chan Zuckerberg Initiative (CZI) Request for Applications: Ben Barres Early Career Acceleration Award RFA
Description: The Chan Zuckerberg Initiative invites applications for the second cycle of the Ben Barres Early Career Acceleration Awards. This is an investigator award for early career academic investigators, especially those who are new to the field of neurodegeneration. Awards are $1.2M in total costs over 4 years. Early career investigators will benefit from mentored support and resources of the CZI Neurodegeneration Challenge Network.
Letter of Intent (LOI) Deadline: April 20, 2023
Link to Full Announcement: https://chanzuckerberg.com/rfa/ben-barres-early-career-acceleration-awards/
Robert A. Winn Career Development Award (Winn CDA)
Description: The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations. The program collaborates with communities to facilitate an approach to clinical and translational research that is community-informed, designed, and conducted. It provides emerging investigators the sponsorship, support, and tools they need to conduct clinical trials that will yield new treatments effective in all populations.
Application Deadline: May 12, 2023
Link to Full Announcement: https://diversityinclinicaltrials.org/application-information . Please see the attached flyers.
HRSA Nurse Education, Practice, Quality and Retention (NEPQR)-Pathway to Registered Nurse Program (PRNP) (HRSA-23-016)
Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO). The Nurse Education, Practice, Quality and Retention (NEPQR) - Pathway to Registered Nurse Program (PRNP) aims to create a pathway from academic training to clinical practice through the creation and implementation of Licensed Practical Nurse/Licensed Vocational Nurse (LPN/LVN) to Registered Nurse (RN) Bridge Programs and employment of Clinical Nurse Faculty.
HRSA will award approximately $8.9 million to up to 8 cooperative agreements over a period of four years.
Application Deadline: April 27, 2023
Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-016?UTM_campaign=NOFO
DoD Ovarian Cancer Research Program (OCRP)
- Investigator-Initiated Research Award (IIRA)
- Ovarian Cancer Academy Award - Early-Career Investigator (OCA)
- Pilot Award (PA)
Pre-Application: April 17, 2023
Application: July 21, 2023
- Clinical Translational Research Award
- Clinical Trial Award
- Ovarian Cancer Clinical Trial Academy - Leadership Award
Pre-Application: May 26, 2023
Application: July 21, 2023
Link to Full Announcement: https://cdmrp.health.mil/funding/ocrp
The Leona M. and Harry B. Helmsley Charitable Trust- Request for Applications to advance collaborative research in T1D prevention
Description: This RFP supported in collaboration with JDRF Australia, seeks collaborative projects to help answer unknowns about T1D biological mechanisms, with studies on its samples and data collected from pregnancy through childhood from children with an immediate family member with T1D.
LOI Deadline: April 7, 2023
Link to Full Announcement: https://jdrf.org.au/for-researchers/type-1-diabetes-prevention-rfa/
HRSA Advanced Nursing Education Workforce (ANEW) Program (HRSA-23-014)
Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO). The Advanced Nursing Education Workforce (ANEW) Program aims to increase the number of primary care nurse practitioners, clinical nurse specialists, and certified nurse midwives trained and prepared to provide primary care services, mental health and substance use disorder care, and maternal health care. The grants will support the training and graduation of advanced practice registered nursing (APRN) students and trainees in these disciplines.
Application Deadline: April 7, 2023
Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-014?UTM_campaign=Funding+Announcement+-+Advanced+Nursing+Education+Workforce
HRSA Advanced Nursing Education Nurse Practitioner Residency and Fellowship (ANE-NPRF) Program (HRSA-23-009)
Description: The Health Resources and Services Administration (HRSA) released a new Notice of Funding Opportunity (NOFO) for the Advanced Nursing Education Nurse Practitioner Residency and Fellowship (ANE-NPRF) Program, which aims to prepare new Advanced Practice Registered Nurses (APRNs) to effectively provide primary care by supporting transition to practice through the expansion and/or enhancement of existing Nurse Practitioner (NP) residency programs. The program also focuses on the integration of behavioral health and maternal health into primary care by training new primary care providers, behavioral health providers, and certified nurse midwives in community-based settings.
HRSA will award approximately $30 million to up to 43 grantees over a period of four years.
Application Deadline: April 11, 2023
Link to Full Announcement: https://www.hrsa.gov/grants/find-funding/HRSA-23-009?UTM_campaign=NOFO+Announcement+-+ANE+NPRF+Program
DoD Amyotrophic Lateral Sclerosis Research Program (ALSRP)
Pre-Application: 4-13-2023
Application: 7-13-2023
Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495104
DoD Epilepsy Research Program (ERP)
Pre-Application (Letter of Intent): 5-19-2023
Application: 6-23-2023
Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495101
DoD Peer Reviewed Medical Research Program (PRMRP)
Pre-Application (Letter of Intent): 4-12-2023
Application: 7-19-2023
Pre-Application (Letter of Intent): 4-12-2023
Application: 7-19-2023
Pre-Application (Letter of Intent): 4-19-2023
Application: 5-31-2023
Pre-Application (Letter of Intent): 4-19-2023
Application: 5-31-2023
Pre-Application (Letter of Intent): 4-19-2023
Application: 5-31-2023
Link to Full Announcement: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=495103
The International Center for Responsible Gaming - REQUEST FOR APPLICATIONS ON RESEARCH ON PRE-COMMITMENT AS A PREVENTION MEASURE TO REDUCE GAMBLING-RELATED HARMS
Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for a two-year Large Grant to study the effectiveness of “pre-commitment,” a prevention strategy that encourages gamblers to set limits on money and time spent gambling. Applicants may request up to a total of $75,000 per year for up to two years plus 15 percent in Facilities & Administration costs. Total amount that may be requested is $172,500.
Application Deadline: May 15, 2023
Link to Full Announcement: https://www.icrg.org/information/apply-for-icrg-funding